Navigation Links
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
Date:7/31/2014

SAN FRANCISCO, July 31, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2014.

Cash and investments in marketable securities at June 30, 2014 were $301.4 million as compared to $309.1 million at March 31, 2014."The second half of 2014 will be an exciting time for Nektar as we look forward to significant milestones for a number of our late-stage clinical programs," said Howard W. Robin, President and Chief Executive Officer of Nektar. "The first of these is the potential US and EU approvals of Movantik™ with our partner AstraZeneca. If approved, Movantik would be the first oral targeted therapy approved for opioid induced constipation, a debilitating condition that occurs in up to 80%* of the 69 million chronic pain patients worldwide. Our partner Baxter has completed dosing in their Phase 3 study for BAX 855, a longer-acting PEGylated Factor VIII therapy to treat hemophilia A and plans to file the BLA in the U.S. by the end of this year. In our proprietary pipeline, we are on track for topline results from the Phase 3 breast cancer study for NKTR-102 in Q1 2015."

Revenue in the second quarter of 2014 was $28.5 million as compared to $33.9 million in the second quarter of 2013. Year-to-date revenue for 2014 was $48.3 million as compared to $56.9 million in the first half of 2013.  The decrease in revenue in the second quarter and first half of 2014 as compared to the same periods in 2013 is primarily due to decreased manufacturing activity.  Revenue included non-cash royalty revenue, related to our 2012 royalty monetization, of $4.8 million and $10.6 million in the second quarter and first half of 2014, respectively, and $3.8 million and $8.2 million in the second quarter and first half of 2013, respectively. This non-cash royalty revenue is offset by non-cash interest exp
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
4. Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
5. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
6. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
7. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
8. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
9. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
10. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
11. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... PHILADELPHIA , Sept. 1, 2015 ... in sleep therapy, and HGE Health Care Solutions, ... management, announced today a comprehensive sleep management and ... Apnea (OSA). OSA is a chronic ... during sleep and may increase a patient,s risk ...
(Date:9/1/2015)... 2015   Millstone Medical Outsourcing announced today that ... Olive Branch, MS. Now totaling over ... facility has added the capacity required to meet the high ... expansion gives us the opportunity to grow in parallel with ... MS. "Two and a half years ago we were operating ...
(Date:9/1/2015)... 1, 2015 VolitionRx Limited (NYSE MKT: ... tests for a broad range of cancer types and other ... Reynolds , is scheduled to attend the 10 th ... 9-10, 2015 in Boston, Massachusetts . VolitionRx ... Wells Fargo Securities Research conferences are among the ...
Breaking Medicine Technology:Sleep Specialists, LLC and HGE Health Care Solutions Announce Comprehensive Sleep Program 2Millstone Medical Outsourcing Announces Olive Branch Expansion 2VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 2VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 3VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 4
... Ltd today announced that the National University Hospital (NUH), ... IRB equivalent) provisional approval for a new study: ... /DIEP Flap - Comparison of TIGR (100% Resorbable) vs ... randomized study, involving 86 patients. There are plans to ...
... Sept. 13 Three people living with diabetes can realize ... Bayer Diabetes Care,s "Give Back. Simply Win." Contest. Sponsored by ... on people with diabetes who are making a difference in ... Nick Jonas and a donation by Bayer of $5,000 to ...
Cached Medicine Technology:National University Hospital Singapore Receives DSRB Approval to Use TIGR® Matrix Surgical Mesh in a New Randomized Controlled TRAM Flap Study 2Nick Jonas and Bayer Diabetes Care Enable Winners of the 'Give Back. Simply Win.' Contest to Realize Their Dream to Help Others 2Nick Jonas and Bayer Diabetes Care Enable Winners of the 'Give Back. Simply Win.' Contest to Realize Their Dream to Help Others 3
(Date:9/2/2015)... ... September 02, 2015 , ... Canopy ... been named to the Inc. 5000 List, an independent ranking of the ... for 34 years, and this achievement puts Canopy in rarefied company. Over the ...
(Date:9/2/2015)... ... September 02, 2015 , ... Traveling to the Caribbean ... array of magnificent flora and fauna. , Lifestyle Holidays Vacation Club knows ... To help make travelers experience that much better, Lifestyle Holidays Vacation Club has put ...
(Date:9/1/2015)... ... September 01, 2015 , ... September is National Prostate Cancer ... affects more than 233,000 men each year in the United States. , Prostate cancer ... non-skin cancer in America, affecting 1 in 7 men. One new case occurs every ...
(Date:9/1/2015)... ... ... Earth Brands, ( http://www.earthbrands.com ) a comfort-meets-fashion women’s footwear ... an Earth Brand shoe will be given an opportunity to plant a tree ... nonprofit dedicated to planting more trees. Earth Brands products represent contemporary designs and ...
(Date:9/1/2015)... ... September 01, 2015 , ... Stress comes ... created from everyday life changes can lead to very serious, life-altering events. Fortunately ... coping with stress. Herbal supplement manufacturer MediHerb has coupled therapeutic doses ...
Breaking Medicine News(10 mins):Health News:Canopy Partners Named to 2015 Inc. 5000 Fastest Growing Companies List 2Health News:Lifestyle Holidays Vacation Club Lists 3 Things to Consider When On a Puerto Plata Vacation 2Health News:Lifestyle Holidays Vacation Club Lists 3 Things to Consider When On a Puerto Plata Vacation 3Health News:September is Prostate Cancer Awareness Month 2Health News:September is Prostate Cancer Awareness Month 3Health News:Earth Brands Footwear Partners with Trees for the Future for Launch of Fall Collection: Buy Shoes, Plant a Tree 2Health News:Earth Brands Footwear Partners with Trees for the Future for Launch of Fall Collection: Buy Shoes, Plant a Tree 3Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 2Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 3
... San Diego, California, May 19, 2008 NPS Pharmaceuticals, ... 3 data at the annual Digestive Disease Week (DDW) ... may reduce dependence upon parenteral nutrition (PN) in patients ... (SBS). , The Phase 3 study evaluated ...
... counties - Los Angeles, Alameda, Contra Costa, San Mateo, San Francisco, ... ... Procedures, WOODLAND HILLS, Calif., May 19 ... initiative into California. Now, approximately 1.8 million of,Anthem Blue Cross members in ...
... of developing reliable genetic tests to guide lung cancer ... University recently evaluated the ability of five high-risk genetic ... would recur in patients whose non-small cell lung cancer ... their findings at the American Thoracic Societys 2008 International ...
... 19 Towards the Electronic,Patient Record (TEPR) ... terminology,announced today its next-generation interface terminology delivery ... access to all of,IMO,s terminology knowledge sources. ... optimized for millisecond response times in a ...
... Million Verdict Upheld Against Mesothelioma Victim,s Former Employers, ... fifteen months after,winning a $3.2 million verdict against ... Constructors, Inc. on behalf of,mesothelioma victim Ray Rando, ... been affirmed by the Louisiana First Circuit Court ...
... surgeon at the University of Liverpool has performed a groundbreaking ... more commonly seen in dogs. , The three year-old chimp ... year and now lives in a chimpanzee reserve supported by ... and had difficulty walking because a bone in her forearm ...
Cached Medicine News:Health News:Phase 3 GATTEX results presented at DDW highlight potential new treatment in short bowel syndrome 2Health News:Phase 3 GATTEX results presented at DDW highlight potential new treatment in short bowel syndrome 3Health News:Phase 3 GATTEX results presented at DDW highlight potential new treatment in short bowel syndrome 4Health News:Anthem Blue Cross Introduces Industry's Most Comprehensive Transparency Initiative to California 2Health News:Anthem Blue Cross Introduces Industry's Most Comprehensive Transparency Initiative to California 3Health News:Will lung cancer recur? A genetic test may provide the answer 2Health News:Intelligent Medical Objects (IMO), Inc. announces the General Availability of Its Terminology Portal Service for EMR/EHR and Charge-Capture Applications 2Health News:Intelligent Medical Objects (IMO), Inc. announces the General Availability of Its Terminology Portal Service for EMR/EHR and Charge-Capture Applications 3Health News:Intelligent Medical Objects (IMO), Inc. announces the General Availability of Its Terminology Portal Service for EMR/EHR and Charge-Capture Applications 4Health News:Asbestos Verdict Upheld by Louisiana Court of Appeal, Announces Baron & Budd 2Health News:Surgeon operates to rescue chimp with rare deformity 2
Synchron Hemoglobin A1c (HbA1c) utilizes two unique cartridges, Hb and A1c, to determine HbA1c concentration as a percentage of total hemoglobin....
Micromat II Hemoglobin A1c instrument is an easy-to-use, accurate and precise instrument with an requirement of only 10 L of capillary or venous sample....
... a manual hemostasis analyzer that is ... - PTs, aPTTs, thrombins, fibrinogens and ... low-volume testing, this analyzer is small ... offering time and labor saving benefits. ...
... Description,The STA-R Evolution is a fully-automated, ... the total laboratory automation line. Clotting, ... simultaneously in random access mode. The ... offers high throughput and rapid processing ...
Medicine Products: